Neuromodulation Market Overview
Neuromodulation is defined by the International Neuromodulation Society (INS) as a field of science, medicine, and bioengineering that encompasses implantable and non-implantable technologies, electrical or chemical, that impact upon neural interfaces to improve life for humanity. Neurological disorders such as epilepsy, Alzheimer's disease, cerebrovascular diseases, and Parkinson's disease affect the central and peripheral nervous systems. To manage such disorders, neuromodulation is used.
The global Neuromodulation Market is mainly driven by the increasing incidence of neurological diseases, such as Alzheimer’s and Parkinson’s diseases across the world. According to World Health Organization, worldwide, around 50 million people have dementia, and there are nearly 10 million new cases every year. Alzheimer's disease is the most common form of dementia and may contribute to 60–70% of cases. Moreover, other factors such as the rising old age population and their vulnerability for neurological disorders and growing awareness regarding the safety and efficacy of neurostimulator devices are remarkably contributing to the growth of the Neuromodulation Market.
On the other hand, lack of trained healthcare professionals and stringent approval policies, are expected to hamper the growth of the market.
Covid-19 Impact on Neuromodulation Market
In addition, the current Neuromodulation Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Neuromodulation Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Neuromodulation Market Segment Overview
According to technology, the Spinal Cord Stimulation segment has significant growth in the Neuromodulation market. The spinal cord stimulation (SCS) has huge potential to treat widespread chronic back pain. Around 20% of adult Americans experience chronic pain. Recently, USFDA and similar regulatory agencies have approved many products of the SCS technology. The use of technology is expanding to new indications such as failed back surgery syndrome, refractory angina pectoris, peripheral vascular disease, and complex regional pain syndrome. Additionally, Deep Brain Stimulation (DBS) segment is expected to show noteworthy growth owing to the high adoption rate in developed countries for neurological disorders, such as Parkinson’s disease. The use of DBS is mainly in severe obsessive-compulsive disorder, treatment-resistant depression, Alzheimer's type dementia, and movement disorders.
Neuromodulation Market, By Technology
· Chronic Pain Management
· Failed back syndrome
· Epilepsy
· Tremor
· Urinary and Fecal Incontinence
· Depression
· Dystonia
· Gastroparesis
· Parkinson's disease
· Obsessive-Compulsive Disorder
· Migraine
· Other
Neuromodulation Market, By Biomaterial
· Metallic Biomaterials
· Polymeric Biomaterials
· Ceramic Biomaterials
Neuromodulation Regional Overview
Region-wise, North America is the most significant region in the global neuromodulation market and is anticipated to be the first preference for new competitors due to the increasing end-use in the region. Similarly, the market in the Asia Pacific is anticipated to expand at a rapid pace in the coming years. Factors such as government and private initiatives to increase awareness regarding mental health and increasing incidences of neurological disorders boost the market’s growth in the Asia Pacific. In addition to this, Japan has the highest revenue share in the region, followed by China. India is expected to witness rapid growth in the future due to increasing awareness regarding mental disorders and growing expenditure in the healthcare sector.
Neuromodulation Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Neuromodulation Market Competitor overview
Some key developments and strategies adopted by manufacturers in Neuromodulation are highlighted below.
· In July 2021, Merck KGaA has tapped a Spanish startup to help it build a new approach to bioelectronic therapies. The aim is to use graphene to target multiple chronic diseases through selective nerve stimulation.
Neuromodulation Market, Key Players
· Medtronic plc
· St. Jude Medical, Inc.
· LivaNova PLC
· Boston Scientific Corporation
· Aleva Neurotherapeutics SA
· BioControl Medical
· Bioness Inc.
· EnteroMedics Inc
· Nevro Corporation and NeuroPace Inc.
Neuromodulation is defined by the International Neuromodulation Society (INS) as a field of science, medicine, and bioengineering that encompasses implantable and non-implantable technologies, electrical or chemical, that impact upon neural interfaces to improve life for humanity. Neurological disorders such as epilepsy, Alzheimer's disease, cerebrovascular diseases, and Parkinson's disease affect the central and peripheral nervous systems. To manage such disorders, neuromodulation is used.
The global Neuromodulation Market is mainly driven by the increasing incidence of neurological diseases, such as Alzheimer’s and Parkinson’s diseases across the world. According to World Health Organization, worldwide, around 50 million people have dementia, and there are nearly 10 million new cases every year. Alzheimer's disease is the most common form of dementia and may contribute to 60–70% of cases. Moreover, other factors such as the rising old age population and their vulnerability for neurological disorders and growing awareness regarding the safety and efficacy of neurostimulator devices are remarkably contributing to the growth of the Neuromodulation Market.
On the other hand, lack of trained healthcare professionals and stringent approval policies, are expected to hamper the growth of the market.
Covid-19 Impact on Neuromodulation Market
In addition, the current Neuromodulation Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Neuromodulation Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Neuromodulation Market Segment Overview
According to technology, the Spinal Cord Stimulation segment has significant growth in the Neuromodulation market. The spinal cord stimulation (SCS) has huge potential to treat widespread chronic back pain. Around 20% of adult Americans experience chronic pain. Recently, USFDA and similar regulatory agencies have approved many products of the SCS technology. The use of technology is expanding to new indications such as failed back surgery syndrome, refractory angina pectoris, peripheral vascular disease, and complex regional pain syndrome. Additionally, Deep Brain Stimulation (DBS) segment is expected to show noteworthy growth owing to the high adoption rate in developed countries for neurological disorders, such as Parkinson’s disease. The use of DBS is mainly in severe obsessive-compulsive disorder, treatment-resistant depression, Alzheimer's type dementia, and movement disorders.
Neuromodulation Market, By Technology
- Internal neuromodulation
- Deep Brain Stimulation
- Sacral Nerve Stimulation
- Vagus Nerve Stimulation
- Spinal Cord Stimulation
- Other Neuromodulation Technologies
- External neuromodulation
- Transcutaneous Electrical Nerve Stimulation
- Transcranial Magnetic Stimulation
· Chronic Pain Management
· Failed back syndrome
· Epilepsy
· Tremor
· Urinary and Fecal Incontinence
· Depression
· Dystonia
· Gastroparesis
· Parkinson's disease
· Obsessive-Compulsive Disorder
· Migraine
· Other
Neuromodulation Market, By Biomaterial
· Metallic Biomaterials
· Polymeric Biomaterials
· Ceramic Biomaterials
Neuromodulation Regional Overview
Region-wise, North America is the most significant region in the global neuromodulation market and is anticipated to be the first preference for new competitors due to the increasing end-use in the region. Similarly, the market in the Asia Pacific is anticipated to expand at a rapid pace in the coming years. Factors such as government and private initiatives to increase awareness regarding mental health and increasing incidences of neurological disorders boost the market’s growth in the Asia Pacific. In addition to this, Japan has the highest revenue share in the region, followed by China. India is expected to witness rapid growth in the future due to increasing awareness regarding mental disorders and growing expenditure in the healthcare sector.
Neuromodulation Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Neuromodulation Market Competitor overview
Some key developments and strategies adopted by manufacturers in Neuromodulation are highlighted below.
· In July 2021, Merck KGaA has tapped a Spanish startup to help it build a new approach to bioelectronic therapies. The aim is to use graphene to target multiple chronic diseases through selective nerve stimulation.
Neuromodulation Market, Key Players
· Medtronic plc
· St. Jude Medical, Inc.
· LivaNova PLC
· Boston Scientific Corporation
· Aleva Neurotherapeutics SA
· BioControl Medical
· Bioness Inc.
· EnteroMedics Inc
· Nevro Corporation and NeuroPace Inc.
Neuromodulation Market Study Global Market Analysis, Insights and Forecast, 2020-20275.3. Market Analysis, Insights and Forecast – By Application 5.4. Market Analysis, Insights and Forecast – By Biomaterial 5.5. Market Analysis, Insights and Forecast – By Region 6.3. Market Analysis, Insights and Forecast – By Application 6.4. Market Analysis, Insights and Forecast – By Biomaterial 6.5. Market Analysis, Insights and Forecast – By Country 7.3. Market Analysis, Insights and Forecast – By Application 7.4. Market Analysis, Insights and Forecast – By Biomaterial 7.5. Market Analysis, Insights and Forecast – By Country 8.3. Market Analysis, Insights and Forecast – By Application 8.4. Market Analysis, Insights and Forecast – By Biomaterial 8.5. Market Analysis, Insights and Forecast – By Country 9.3. Market Analysis, Insights and Forecast – By Application 9.4. Market Analysis, Insights and Forecast – By Biomaterial 9.5. Market Analysis, Insights and Forecast – By Country
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Neuromodulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Technology
- 5.2.1. Internal neuromodulation
- 5.2.1.1. Deep Brain Stimulation
- 5.2.1.2. Sacral Nerve Stimulation
- 5.2.1.3. Vagus Nerve Stimulation
- 5.2.1.4. Spinal Cord Stimulation
- 5.2.1.5. Other Neuromodulation Technologies
- 5.2.2. External neuromodulation
- 5.2.2.1. Transcutaneous Electrical Nerve Stimulation
- 5.2.2.2. Transcranial Magnetic Stimulation
- 5.2.1. Internal neuromodulation
- 5.3.1. Chronic Pain Management
- 5.3.2. Failed back syndrome
- 5.3.3. Epilepsy
- 5.3.4. Tremor
- 5.3.5. Urinary and Fecal Incontinence
- 5.3.6. Depression
- 5.3.7. Dystonia
- 5.3.8. Gastroparesis
- 5.3.9. Parkinson's disease
- 5.3.10. Obsessive-Compulsive Disorder
- 5.3.11. Migraine
- 5.3.12. Other
- 5.4.1. Metallic Biomaterials
- 5.4.2. Polymeric Biomaterials
- 5.4.3. Ceramic Biomaterials
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America, Middle East and Africa
6. North America Neuromodulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Technology
- 6.2.1. Internal neuromodulation
- 6.2.1.1. Deep Brain Stimulation
- 6.2.1.2. Sacral Nerve Stimulation
- 6.2.1.3. Vagus Nerve Stimulation
- 6.2.1.4. Spinal Cord Stimulation
- 6.2.1.5. Other Neuromodulation Technologies
- 6.2.2. External neuromodulation
- 6.2.2.1. Transcutaneous Electrical Nerve Stimulation
- 6.2.2.2. Transcranial Magnetic Stimulation
- 6.2.1. Internal neuromodulation
- 6.3.1. Chronic Pain Management
- 6.3.2. Failed back syndrome
- 6.3.3. Epilepsy
- 6.3.4. Tremor
- 6.3.5. Urinary and Fecal Incontinence
- 6.3.6. Depression
- 6.3.7. Dystonia
- 6.3.8. Gastroparesis
- 6.3.9. Parkinson's disease
- 6.3.10. Obsessive-Compulsive Disorder
- 6.3.11. Migraine
- 6.3.12. Other
- 6.4.1. Metallic Biomaterials
- 6.4.2. Polymeric Biomaterials
- 6.4.3. Ceramic Biomaterials
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Neuromodulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Technology
- 7.2.1. Internal neuromodulation
- 7.2.1.1. Deep Brain Stimulation
- 7.2.1.2. Sacral Nerve Stimulation
- 7.2.1.3. Vagus Nerve Stimulation
- 7.2.1.4. Spinal Cord Stimulation
- 7.2.1.5. Other Neuromodulation Technologies
- 7.2.2. External neuromodulation
- 7.2.2.1. Transcutaneous Electrical Nerve Stimulation
- 7.2.2.2. Transcranial Magnetic Stimulation
- 7.2.1. Internal neuromodulation
- 7.3.1. Chronic Pain Management
- 7.3.2. Failed back syndrome
- 7.3.3. Epilepsy
- 7.3.4. Tremor
- 7.3.5. Urinary and Fecal Incontinence
- 7.3.6. Depression
- 7.3.7. Dystonia
- 7.3.8. Gastroparesis
- 7.3.9. Parkinson's disease
- 7.3.10. Obsessive-Compulsive Disorder
- 7.3.11. Migraine
- 7.3.12. Other
- 7.4.1. Metallic Biomaterials
- 7.4.2. Polymeric Biomaterials
- 7.4.3. Ceramic Biomaterials
- 7.5.1. UK
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Russia
- 7.5.7. Rest of Europe
8. Asia Pacific Neuromodulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Technology
- 8.2.1. Internal neuromodulation
- 8.2.1.1. Deep Brain Stimulation
- 8.2.1.2. Sacral Nerve Stimulation
- 8.2.1.3. Vagus Nerve Stimulation
- 8.2.1.4. Spinal Cord Stimulation
- 8.2.1.5. Other Neuromodulation Technologies
- 8.2.2. External neuromodulation
- 8.2.2.1. Transcutaneous Electrical Nerve Stimulation
- 8.2.2.2. Transcranial Magnetic Stimulation
- 8.2.1. Internal neuromodulation
- 8.3.1. Chronic Pain Management
- 8.3.2. Failed back syndrome
- 8.3.3. Epilepsy
- 8.3.4. Tremor
- 8.3.5. Urinary and Fecal Incontinence
- 8.3.6. Depression
- 8.3.7. Dystonia
- 8.3.8. Gastroparesis
- 8.3.9. Parkinson's disease
- 8.3.10. Obsessive-Compulsive Disorder
- 8.3.11. Migraine
- 8.3.12. Other
- 8.4.1. Metallic Biomaterials
- 8.4.2. Polymeric Biomaterials
- 8.4.3. Ceramic Biomaterials
- 8.5.1. China
- 8.5.2. India
- 8.5.3. Japan
- 8.5.4. Australia
- 8.5.5. South East Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Neuromodulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Technology
- 9.2.1. Internal neuromodulation
- 9.2.1.1. Deep Brain Stimulation
- 9.2.1.2. Sacral Nerve Stimulation
- 9.2.1.3. Vagus Nerve Stimulation
- 9.2.1.4. Spinal Cord Stimulation
- 9.2.1.5. Other Neuromodulation Technologies
- 9.2.2. External neuromodulation
- 9.2.2.1. Transcutaneous Electrical Nerve Stimulation
- 9.2.2.2. Transcranial Magnetic Stimulation
- 9.2.1. Internal neuromodulation
- 9.3.1. Chronic Pain Management
- 9.3.2. Failed back syndrome
- 9.3.3. Epilepsy
- 9.3.4. Tremor
- 9.3.5. Urinary and Fecal Incontinence
- 9.3.6. Depression
- 9.3.7. Dystonia
- 9.3.8. Gastroparesis
- 9.3.9. Parkinson's disease
- 9.3.10. Obsessive-Compulsive Disorder
- 9.3.11. Migraine
- 9.3.12. Other
- 9.4.1. Metallic Biomaterials
- 9.4.2. Polymeric Biomaterials
- 9.4.3. Ceramic Biomaterials
- 9.5.1. Brazil
- 9.5.2. Saudi Arabia
- 9.5.3. UAE
- 9.5.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Medtronic plc
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. St. Jude Medical, Inc.
- 10.6. LivaNova PLC
- 10.7. Boston Scientific Corporation
- 10.8. Aleva Neurotherapeutics SA
- 10.9. BioControl Medical
- 10.10. Bioness Inc.
- 10.11. EnteroMedics Inc
Research Process
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
